CLINICAL TRIAL

EXCEL Exercise Class for Malignancies

Recruiting · 18+ · All Sexes · Calgary, Canada

EXCEL: Technology and Exercise Adherence

See full description

About the trial for Malignancies

Treatment Groups

This trial involves 2 different treatments. EXCEL Exercise Class is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
EXCEL Exercise Class
BEHAVIORAL
ZoeInsights Application
DEVICE
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
EXCEL Exercise Class
BEHAVIORAL

Eligibility

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Have a cancer diagnosis
Be over the age of 18 years
Be able to participate in mild levels of activity as a minimum (to be assessed during screening via the Physical Activity Readiness Questionnaire)
Be pre-treatment, or receiving active cancer treatment, or have received cancer treatment within the past three year
Be able to provide informed written consent in English
Have access to internet service that can support video calling
Be signed up for the EXCEL baseline class
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Assessed at baseline and weeks 4, 8, 12, 16, 20, 24
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Assessed at baseline and weeks 4, 8, 12, 16, 20, 24.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether EXCEL Exercise Class will improve 3 primary outcomes and 17 secondary outcomes in patients with Malignancies. Measurement will happen over the course of Continuous measurement from baseline to 24 weeks.

Exercise adherence
CONTINUOUS MEASUREMENT FROM BASELINE TO 24 WEEKS
Adherence to exercise programming (attendance at sessions)
ZI application usage
CONTINUOUS MEASUREMENT FROM BASELINE TO 24 WEEKS
Measured directly through the app as logins, tasks completed, pages visited, additional use, and continued usage habits during the maintenance phase
Objective Physical Activity Minutes Per Week
MEASURED CONTINUOUSLY FROM BASELINE TO 24 WEEKS
Change in activity levels from pre to post; Number of participants meeting Guidelines for Physical Activity of 90 minutes per week of moderate to vigorous intensity exercise, based on accelerometer data from commercially-available activity tracker. For the activity tracker each minute in the 55-70 percent age predicted HRmax will be evaluated as moderate intensity and above 70 percent of HRmax will be evaluated as vigorous intensity. Vigorous intensity minutes of physical activity will be doubled and added with moderate intensity minutes to obtain moderate to vigorous physical activity (MVPA) minutes.
Fatigue
ASSESSED AT BASELINE,12-WEEKS (POST-INTERVENTION), AND 24 WEEKS (FOLLOW-UP)
Change in Functional Assessment of Chronic Illness Therapy - Fatigue subscale - scale is from 0-4, where 0 means "not at all" and 4 means "very much".
General Health-related Quality of Life
ASSESSED AT BASELINE,12-WEEKS (POST-INTERVENTION), AND 24 WEEKS (FOLLOW-UP)
Change in EuroQual - 5 Dimensions (EQ-5D) tool. Scores for each item range from 1 to 5, with lower scores indicating better quality of life.
Upper extremity grip strength
ASSESSED AT BASELINE,12-WEEKS (POST-INTERVENTION), AND 24 WEEKS (FOLLOW-UP)
Change in hand-grip dynamometry (kg)
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can malignancies be cured?

A cure is possible for some cancer malignancies, most notably, Hodgkin's lymphoma, breast cancer, and squamous cell carcinoma. However, most malignancies do not seem to be amenable to a potential cure. This article examines the possibility of a cure of these malignancies in a small number of patients and is not a cure by any means. The article addresses the ethics of cure when the life expectancy is less than a few months.

Anonymous Patient Answer

How many people get malignancies a year in the United States?

About half (around 47%) of American adults aged 20 and older have at least one malignancy at some time in their lives. The most common malignancies were breast cancer (8.6 million), lung cancer (3.9 million), colon cancer (2.9 million) and prostate cancer (2.2 million). In total, approximately 10.0 million people in the United States were diagnosed with or died from malignancies in 2000. In contrast with breast cancer, which is often a long-term problem, the average lifetime risk of dying from prostate cancer or lung cancer is comparable to the population as a whole.

Anonymous Patient Answer

What causes malignancies?

Some risk factors for malignancies can be modelled by simple causal models, in which environmental, genetic or behavioural factors are associated with certain pathogenetic pathways. Examples of such associations are as follows: excess lifetime weight gain and overweight/obesity; smoking and [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), and high-serum IGF-I levels and lung cancer among men with cancer. In contrast, risk factors for developing malignancies are usually complex and will normally depend on the host's susceptibility and responsiveness to putative causal factors. For example, a link between breast cancer risk and HRT is very likely due to HRT influencing the ovarian risk factor oestrogen.

Anonymous Patient Answer

What is malignancies?

Malignancies are classified according to the organ or organs in which the primary tumor develops. Most cases of cancer come under the umbrella of malignancies.\n

Anonymous Patient Answer

What are the signs of malignancies?

As there are many cancer types, the signs of cancer depend on the type of cancer. The key signs and symptoms reported by patients are fatigue, unexplained weight loss, cough or difficulty swallowing, and erythema nodosum or skin changes.

Anonymous Patient Answer

What are common treatments for malignancies?

Cancer treatment usually includes the use of many types of chemotherapy drugs or cytotoxic therapy. Chemotherapy is often used in the treatment of lymphoma. A wide variety of anti-cancer drugs are used to treat cancer, including protease inhibitors like indinavir, proteasome inhibitors like bortezomib, and thiol alkylating agents like temozolomide. Radiation therapy is used as first-line therapy for breast cancer. More recently, targeted therapies like erlotinib have been used in the treatment of non-small-cell lung cancer and EGFR inhibitors like erlotinib (Tarceva) have been used in the treatment of EGFR mutated non-small-cell lung cancer.

Anonymous Patient Answer

What are the latest developments in zoeinsights application for therapeutic use?

A new type of therapy for cancer patients, which uses the application system of zoeinsights. This procedure, performed over a period of 6 to 12 months, is recommended for the patients who are not suitable for cytotoxic therapy, or other conventional treatment methods. The treatment of cancer patients with zoeinsight system has already been approved in more than 15 medical centers in the UK. This is a new treatment methodology, which does not involve the use of the cytotoxicity. The therapy consists in the combination of a few types of therapies, including those related to the therapeutic use of this system: physiotherapy, ergotherapeutic, immunotherapy, anti-oncological treatment, physiotherapy, and palliative care.

Anonymous Patient Answer

Have there been any new discoveries for treating malignancies?

Although, the majority of the treatments that target malignancies can reduce the cancer's size, the rate at which the cancer cells continue to grow is unknown, and the survival rate is low.

Anonymous Patient Answer

How does zoeinsights application work?

This ZOEINTS application is one of the first available applications of its kind, and so its findings need to be evaluated by experts in clinical trials. While the results presented are encouraging in demonstrating the potential of ZOEINTS for clinical application, further studies with larger samples are needed.

Anonymous Patient Answer

Is zoeinsights application safe for people?

In this cohort of people, no clinically significant adverse events were found from 1-month of use. This data was not gathered in a time frame that could be considered to be "safe to begin therapy" or "safe to continue therapy" or "safe to discontinue therapy." These data should not influence clinical behavior but should be explored and compared to other similar studies to determine if a longer time frame for use and to evaluate efficacy would be safer for all people using this tool.

Anonymous Patient Answer

What does zoeinsights application usually treat?

Zoeinsights application usually treats the following cancers: renal, prostate, lung, breast, skin, thyroid, colon, and gallbladder. The software evaluates the patient’s tumor and identifies different treatment alternatives with great precision. This helps to identify the risks and benefits of treatments in the patient’s disease and helps optimize their dosage.

Anonymous Patient Answer

Is zoeinsights application typically used in combination with any other treatments?

Results from a recent clinical trial of this paper support the hypothesis that the combination of AIPCs and ZOEINTS may improve patient survival after neoadjuvant treatment.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Malignancies by sharing your contact details with the study coordinator.